Design, Synthesis, Mechanisms of Action, and Toxicity of Novel 20(S)-Sulfonylamidine Derivatives of Camptothecin As Potent Antitumor Agents
Mei-Juan Wang,Ying-Qian Liu,Ling-Chu Chang,Chih-Ya Wang,Yong-Long Zhao,Xiao-Bo Zhao,Keduo Qian,Xiang Nan,Liu Yang,Xiao-Ming Yang,Hsin-Yi Hung,Jai-Sing Yang,Daih-Huang Kuo,Masuo Goto,Susan L. Morris-Natschke,Shiow-Lin Pan,Che-Ming Teng,Sheng-Chu Kuo,Tian-Shung Wu,Yang-Chang Wu,Kuo-Hsiung Lee
DOI: https://doi.org/10.1021/jm5003588
IF: 8.039
2014-01-01
Journal of Medicinal Chemistry
Abstract:Twelve novel 20-sulfonylamidine derivatives (9a–9l) of camptothecin (1) were synthesized via a Cu-catalyzed three-component reaction. They showed similar or superior cytotoxicity compared with that of irinotecan (3) against A-549, DU-145, KB, and multidrug-resistant (MDR) KBvin tumor cell lines. Compound 9a demonstrated better cytotoxicity against MDR cells compared with that of 1 and 3. Mechanistically, 9a induced significant DNA damage by selectively inhibiting Topoisomerase (Topo) I and activating the ATM/Chk related DNA damage-response pathway. In xenograft models, 9a demonstrated significant activity without overt adverse effects at 5 and 10 mg/kg, comparable to 3 at 100 mg/kg. Notably, 9a at 300 mg/kg (i.p.) showed no overt toxicity in contrast to 1 (LD50 56.2 mg/kg, i.p.) and 3 (LD50 177.5 mg/kg, i.p.). Intact 9a inhibited Topo I activity in a cell-free assay in a manner similar to that of 1, confirming that 9a is a new class of Topo I inhibitor. 20-Sulfonylamidine 1-derivative 9a merits development as an anticancer clinical trial candidate.